-+ 0.00%
-+ 0.00%
-+ 0.00%

BioNTech Advances Phase 3 Trial of Pumitamig With Gilead Drug in Triple-Negative Breast Cancer

PUBT·10/22/2026 10:51:26
Listen to the news
BioNTech Advances Phase 3 Trial of Pumitamig With Gilead Drug in Triple-Negative Breast Cancer
  • BioNTech advanced a Phase 3 trial of pumitamig combined with Gilead’s sacituzumab govitecan for triple-negative breast cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioNTech SE published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.